MA54393A - Méthodes de traitement du cancer chez des modèles présentant des mutations esr1 - Google Patents

Méthodes de traitement du cancer chez des modèles présentant des mutations esr1

Info

Publication number
MA54393A
MA54393A MA054393A MA54393A MA54393A MA 54393 A MA54393 A MA 54393A MA 054393 A MA054393 A MA 054393A MA 54393 A MA54393 A MA 54393A MA 54393 A MA54393 A MA 54393A
Authority
MA
Morocco
Prior art keywords
models
cancer treatment
treatment methods
esr1 mutations
esr1
Prior art date
Application number
MA054393A
Other languages
English (en)
French (fr)
Inventor
Heike Arlt
Teeru Bihani
Hitisha Patel
Nianjun Tao
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MA54393A publication Critical patent/MA54393A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA054393A 2018-12-06 2019-12-06 Méthodes de traitement du cancer chez des modèles présentant des mutations esr1 MA54393A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
MA54393A true MA54393A (fr) 2021-10-13

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054393A MA54393A (fr) 2018-12-06 2019-12-06 Méthodes de traitement du cancer chez des modèles présentant des mutations esr1

Country Status (17)

Country Link
US (2) US20220016052A1 (enExample)
EP (1) EP3890835A1 (enExample)
JP (2) JP7497353B2 (enExample)
KR (1) KR20210100135A (enExample)
AU (1) AU2019392908B2 (enExample)
BR (1) BR112021010141A2 (enExample)
CA (1) CA3121918A1 (enExample)
EA (1) EA202191256A1 (enExample)
IL (1) IL283655A (enExample)
JO (1) JOP20210138A1 (enExample)
MA (1) MA54393A (enExample)
MX (1) MX2021006412A (enExample)
MY (1) MY208702A (enExample)
PH (1) PH12021551327A1 (enExample)
SG (1) SG11202105915UA (enExample)
UA (1) UA129588C2 (enExample)
WO (1) WO2020118202A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
MX393599B (es) * 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco

Also Published As

Publication number Publication date
CA3121918A1 (en) 2020-06-11
EA202191256A1 (ru) 2021-10-06
KR20210100135A (ko) 2021-08-13
PH12021551327A1 (en) 2022-04-25
IL283655A (en) 2021-07-29
JP2022511497A (ja) 2022-01-31
JP2024101017A (ja) 2024-07-26
WO2020118202A1 (en) 2020-06-11
EP3890835A1 (en) 2021-10-13
BR112021010141A2 (pt) 2021-08-24
JP7497353B2 (ja) 2024-06-10
AU2019392908A1 (en) 2021-06-10
US20250241875A1 (en) 2025-07-31
MY208702A (en) 2025-05-25
UA129588C2 (uk) 2025-06-11
SG11202105915UA (en) 2021-07-29
AU2019392908B2 (en) 2025-02-20
US20220016052A1 (en) 2022-01-20
MX2021006412A (es) 2021-07-21
JOP20210138A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
IL291633A (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
EP3687981A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
PT3609319T (pt) Modelos de ratinhos e moléculas terapêuticas
MA47121A (fr) Molécules de liaison pour le traitement du cancer
SI3402888T1 (sl) Sredstva in metode za zdravljenje HBV
EP3411802A4 (en) MODELING TRENDS IN CASE OF HARVEST
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
EP3519833A4 (en) PROCEDURE FOR PROGNOSIS AND TREATMENT
EP3423488A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3393475C0 (en) CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER
HUE050095T2 (hu) Anyagcsere-rendellenességek kezelése lófélékben
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
EP3606531A4 (en) METHOD OF TREATMENT OF CANCER
MA47408A (fr) Traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3405203A4 (en) METHOD FOR THE TREATMENT OF CANCER
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
EP3440112A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3353204A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL251903A0 (en) Apilimod for use in the treatment of colorectal cancer
EP3550976A4 (en) METHOD FOR SYNERGISTIC TREATMENT OF CANCER
EP3733175A4 (en) THERAPEUTICS AGAINST CANCER
EP3411073A4 (en) Combinations to treat cancer